CXCL10, a chemokine known to negatively regulate recruitment of anti-tumor immune cells to tumor microenvironment (TME) [17], was elevated post-treatment in patients with NCB, but not in patients with CB (Fig. 1a). Here, CXCL10 is linked to neoplasm.